Abridge — Valuation, Funding & Investors

Abridge builds a generative AI platform that turns clinician-patient conversations into structured, billable clinical documentation, founded in 2018 in the United States. Its Contextual Reasoning Engine powers three tailored experiences, for clinicians, revenue-cycle teams and nurses, integrating directly into EHR workflows including Epic's Haiku and Hyperspace with Linked Evidence to help clinicians verify AI-drafted notes. The platform supports multiple specialties and languages.

Health systems including Kaiser Permanente, Johns Hopkins Medicine, Duke Health and Yale New Haven Health have deployed Abridge at scale, and Christus Health reported a 78% reduction in cognitive load using the platform. Abridge earned the Best in KLAS award for ambient AI in both 2025 and 2026, and is working with Nvidia to train a healthcare-specific AI model.

Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Abridge.

Often trade at a premium or discount to NAV.

Platforms match existing holders with buyers. Abridge availability at any moment is set by the holders.

High minimums, transfer approval, company right-of-first-refusal.

Valuations, rounds and IPO status for every company in the directory — Abridge included.

The closest healthcare technology and ai (ai-powered clinical documentation) peers are on the competitors page.

The routes section explains what is realistically available for a company at this stage.

No. Abridge is a private company; its shares do not trade on a public exchange.

The last valuation is $5.3B (post-money, Apr 2026).